Selective JAK Inhibition in RA vs PV - Top_Thought_Leaders - MDSpire

Selective JAK Inhibition in RA vs PV

Tofacitinib induced remission of rheumatoid arthritis but spared JAK2-driven polycythemia vera in a single case report.

  • By

  • Julia Cipriano

  • February 13, 2026

  • 3 min

Share

Top Thought Leaders in Pathology

Brief introduction explaining scope and methodology.

Original Source(s)

Selective JAK Inhibition in RA vs PV

  • by Julia Cipriano

  • February 13, 2026

Related Content

Curbing Drug-Related Halitosis for Closer Moments

Individuals who have drug-related halitosis may need to take additional steps to prioritize oral health before intimate encounters.

Exploration of country-specific barriers and facilitators for the implementation of physical activity according to the EULAR physical activity recommendations for people with rheumatic musculoskeletal diseases in four different European countries: the COPA project

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.